[Clinical efficacy and T-lymphocyte subset, serum interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-2(IL-2) levels on treatment of chronic aplastic anemia patients by shenfu injection combined with stanozol and cyclosporin A].
OBJECTIVE
To observe the effect of Shenfu injection (SFI) and influence on T-lymphocyte subset, serum level of interferon-gamma(IFN-gamma), tumor necrosis factor-alpha(TNF-alpha), interleukin-2(IL-2) in patients with chronic aplastic anemia (CAA) based on treating with stanozol and cyclosporin A.


METHODS
60 patients with CAA were randomly divided into two groups, 30 patients in the SFI group were treated with SFI (100 mL which contains Ginsenoside 0.8 mg x mL(-1) and aconitine 1.8 microg x mL(-1) by adding it in 500 mL of 5% glucose every day) plus stanozol and cyclosporin A and 30 patients in the control group treated with slanozol and cyclosporin A alone for 2 months. The clinical efficacy was observed. The change of T-lymphocyte subset analyzed by flow cytometry and the levels of serum IFN-gamma, TNF-alpha, IL-2 measured with ELISA method were also observed before and after treatment.


RESULTS
After treatment, the total effective rate of the SFI group was higher than that in the control group, but it did not showing significant difference. The CD4/CD8 levels were significantly increased (1.76+/-0.49, P< 0.01) and CD8 levels were significantly lowered (22.57+/-6.30, P < 0.01) in the SFI group after treatment. Serum levels of lFN-gamma, TNF-alpha and IL-2 were lower in both groups, and the level of TNF-alpha and IL-2 in the SFI group (0.710+/-0.213) ng x L(-1) and (0.639+/-0.247) ng x L(-1) was significantly lowered than that in the control group (P < 0.05, P < 0.01).


CONCLUSIONS
SFI might believe the hemopoietic inhibition so as to promote the recovery of hemopoietic function through improving the T-lymphocyte subset and reducing the release of hemopoietic negative regulatory factors such as IFN-gamma, TNF-alpha and IL-2.
Wang
Su-yun
SY
Department of Hematology, Hebei Provincial People's Hospital, Shijiazhuang 050051, China.
Wei
Ying-fei
YF
Du
Hui-lan
HL
Ren
Li-li
LL
Li
Shi-hui
SH
D000157:Aconitine / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016516:CD4-CD8 Ratio; D016572:Cyclosporine / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D036145:Ginsenosides / Q000008:administration & dosage; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D007376:Interleukin-2 / Q000097:blood*; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D008517:Phytotherapy; D013197:Stanozolol / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D016711:Yang Deficiency / Q000097:blood / Q000188:drug therapy / Q000276:immunology
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D036145:Ginsenosides; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D013197:Stanozolol; D007371:Interferon-gamma; D016572:Cyclosporine; D000157:Aconitine